Virtual Library

Start Your Search

M. Filipska

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      24P - Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) inhibition with AZD1208 to prevent resistance to osimertinib in EGFR mutant NSCLC (ID 399)

      12:30 - 13:00  |  Author(s): M. Filipska

      • Abstract
      • Slides

      Although treatment with EGFR tyrosine kinase inhibitors (TKIs) is initially effective in a subgroup of lung cancer patients, therapy resistance ultimately occurs. Resistance mechanisms consist of overexpression and co-expression of receptor tyrosine kinases (RTKs) and overexpression of STAT3. PIM1 was shown to be an important regulator of both RTKs and STAT3 expression, and inhibition of PIM1 with the pan-PIM inhibitor, AZD1208, might prevent STAT3 and RTK up-regulation after TKI treatment. This research focuses on combining TKI treatment with AZD1208 to prevent therapy resistance in different EGFR mutant NSCLC cell lines.

      Using TaqMan quantitative-PCR we studied basal mRNA expression levels of PIM1 and PIM3 in 5 EGFR-mutant NSCLC cell lines. Cells were then exposed to single osimertinib or AZD1208 treatment, or the combination, to determine the combination index (CI) and changes in cell viability. Moreover, changes in protein expression of different RTKs, STAT3 and downstream effectors of STAT3 were studied in 2 cell lines using western blotting.

      The PC9 and H1975 cell lines were shown to have high PIM1 and STAT3 expression compared to the other EGFR mutant NSCLC cell lines. Combined osimertinib and AZD1208 treatment showed moderate synergism in all cell lines, with CIs ranging from 0.75 to 0.86 in triplicate experiments. Western blot experiments indicate that osimertinib treatment leads to upregulation of pCDCP1, pYAP1, pPaxillin and pSTAT3 in the PC9 and H1975 cell lines, suggesting initiation of resistance to single osimertinib treatment. In contrast, single AZD1208 treatment does not induce, or even lower expression of these proteins compared to baseline levels. When combining both treatments, the osimertinib-induced pSTAT3 up-regulation can be prevented with AZD1208. The effect of AZD1208 on RTK expression will be further explored.

      Single TKI treatment in EGFR mutant NSCLC induces expression of RTKs and STAT3, ultimately leading to therapy resistance. Inhibition of PIM1 with AZD1208 can abolish the osimertinib-induced phosphorylation of STAT3, and thereby prevents activation of resistance pathways.

      Clinical trial identification:

      Legal entity responsible for the study:
      IGTP, Germans Trias i Pujol Research Institute, Badalona, Barcelona, Spain

      Fundació Obra Social “La Caixa”

      All authors have declared no conflicts of interest.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.